World Library  
Flag as Inappropriate
Email this Article

Patent ductus arteriosus

Article Id: WHEBN0000567589
Reproduction Date:

Title: Patent ductus arteriosus  
Author: World Heritage Encyclopedia
Language: English
Subject: Indometacin, Ibuprofen, Functional murmur, Pulse pressure, Congenital disorder
Collection: Congenital Heart Disease, Neonatology
Publisher: World Heritage Encyclopedia

Patent ductus arteriosus

Patent ductus arteriosus
Heart cross-section with PDA
Classification and external resources
Specialty Cardiac surgery
ICD-10 Q25.0
ICD-9-CM 747.0
OMIM 607411
DiseasesDB 9706
MedlinePlus 001560
eMedicine emerg/358
MeSH C14.240.400.340

Patent ductus arteriosus (PDA) is a congenital heart defect wherein the ductus arteriosus fails to close after birth. Early symptoms are uncommon, but in the first year of life include increased work of breathing and poor weight gain. An uncorrected PDA may lead to congestive heart failure with increasing age.

The ductus arteriosus is a fetal blood vessel that closes soon after birth. In a PDA, the vessel does not close and remains "patent" (open), resulting in irregular transmission of blood between the aorta and the pulmonary artery. PDA is common in newborns with persistent respiratory problems such as hypoxia, and has a high occurrence in premature newborns. Premature newborns are more likely to be hypoxic and have PDA due to underdevelopment of the heart and lungs.

A PDA allows a portion of the oxygenated blood from the left heart to flow back to the lungs by flowing from the aorta (which has higher pressure) to the pulmonary artery. If this shunt is substantial, the neonate becomes short of breath: the additional fluid returning to the lungs increases lung pressure, which in turn increases the energy required to inflate the lungs. This uses more calories than normal and often interferes with feeding in infancy. This condition, as a constellation of findings, is called congestive heart failure.

In some congenital heart defects (such as in transposition of the great vessels) a PDA may need to remain open, as it is the only way that oxygenated blood can mix with deoxygenated blood. In these cases, prostaglandins are used to keep the DA open until surgical correction of the heart defect is completed.


  • Signs and symptoms 1
  • Cause 2
  • Diagnosis 3
    • Normal anatomy 3.1
  • Prevention 4
  • Treatment 5
  • Prognosis 6
  • History 7
  • Adult 8
  • References 9
  • External links 10

Signs and symptoms

Common symptoms include:

Patients typically present in good health, with normal respirations and heart rate. If the PDA is moderate or large, widened pulse pressure and bounding peripheral pulses are frequently present, reflecting increased left ventricular stroke volume and diastolic run-off of blood into the (initially lower-resistance) pulmonary vascular bed. Prominent suprasternal and carotid pulsations may be noted secondary to increased left ventricular stroke volume.


A PDA is sometimes idiopathic. Known risk factors include:


Phonocardiograms from normal and abnormal heart sounds

PDA is usually diagnosed using noninvasive techniques. Echocardiography (in which sound waves are used to capture the motion of the heart) and associated Doppler studies are the primary methods of detecting PDA. Electrocardiography (ECG), in which electrodes are used to record the electrical activity of the heart, is not particularly helpful as no specific rhythms or ECG patterns can be used to detect PDA.[2]

A chest X-ray may be taken, which reveals overall heart size (as a reflection of the combined mass of the cardiac chambers) and the appearance of blood flow to the lungs. A small PDA most often accompanies a normal-sized heart and normal blood flow to the lungs. A large PDA generally accompanies an enlarged cardiac silhouette and increased blood flow to the lungs.

Normal anatomy

In the developing fetus, the DA is the vascular connection between the pulmonary artery and the aortic arch that allows most of the blood from the right ventricle to bypass the fetus' lungs, which are fluid-filled and compressed. During fetal development, this shunt protects the right ventricle from pumping against the high resistance in the lungs, which can lead to right ventricular failure if the DA closes in utero.

When the newborn takes his or her first breath, the lungs open and pulmonary vascular resistance decreases. After birth, the lungs release bradykinin to constrict the smooth muscle wall of the DA and reduce blood flow as it narrows and then completely closes. In most newborns with a patent ductus arteriosus, the blood flow is reversed from that of in utero flow; i.e., the blood flow is from the higher-pressure aorta to the now lower-pressure pulmonary arteries.

In normal newborns, the DA is substantially narrowed within 12–24 hours after birth, and seals completely after three weeks. The primary stimulus for closure of the DA is an increase in neonatal blood oxygen content. Withdrawal from maternal circulating prostaglandins also contributes to ductal closure. The residual scar tissue from the fibrotic remnants of the DA, called the ligamentum arteriosum, remains in the normal adult heart.


Some evidence suggests that indomethacin administration on the first day of life to all preterm infants reduces the risk of developing a PDA and the complications associated with PDA. Indomethacin treatment in premature infants also may reduce the need for surgical intervention.[3]


Neonates without adverse symptoms may simply be monitored as outpatients, while symptomatic PDA can be treated with both surgical and non-surgical methods.[4] Surgically, the DA may be closed by ligation (though support in premature infants is mixed),[5] either manually tied shut, or with intravascular coils or plugs that leads to formation of a thrombus in the DA.

Devices developed by Franz Freudenthal block the blood vessel with woven structures of nitinol wire.[6]

Because prostaglandin E2 is responsible for keeping the DA open, NSAIDS (which can inhibit prostaglandin synthesis) such as indomethacin or a special form of ibuprofen have been used to initiate PDA closure. [7][1][8] Recent findings from a systematic review concluded that, for closure of a PDA in preterm and/or low birth weight infants, ibuprofen is as effective as Indomethacin. It also causes fewer side effects (such as transient renal insufficiency) and reduces the risk of necrotising enterocolitis. [9] Another recent review showed that paracetamol may be effective for closure of a PDA in preterm infants. [10]

More recently, PDAs can be closed by percutaneous interventional method (avoiding open heart surgery). A platinum coil can be deployed via a catheter through the femoral vein or femoral artery, which induces thrombosis (coil embolization). Alternatively, a PDA occluder device , composed of nitinol mesh, is deployed from the pulmonary artery through the PDA.


If left untreated, the disease may progress from left-to-right shunt (acyanotic heart) to right-to-left shunt (cyanotic heart), called Eisenmenger's syndrome. Pulmonary hypertension is a potential long-term outcome, which may require a heart and/or lung transplant. Another complication of PDA is intraventricular hemorrhage.


Robert E. Gross, MD performed the first successful ligation of a patent ductus arteriosus on an eight-year-old girl at Children's Hospital Boston in 1938.[11]


Since PDA is usually identified in infants, it is less common in adults, but it can have serious consequences, and is usually corrected surgically upon diagnosis.


  1. ^ a b MedlinePlus > Patent ductus arteriosus Update Date: 21 December 2009
  2. ^ "Tests and Diagnosis".  
  3. ^ Fowlie, PW; Davis PG; McGuire W (19 May 2010). "Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants (Review)". The Cochrane Database of Systematic Reviews (7): CD000174.  
  4. ^ Zahaka, KG and Patel, CR. "Congenital defects'". Fanaroff, AA and Martin, RJ (eds.). Neonatal-perinatal medicine: Diseases of the fetus and infant. 7th ed. (2002):1120-1139. St. Louis: Mosby.
  5. ^ Mosalli R, Alfaleh K, Paes B (July 2009). "Role of prophylactic surgical ligation of patent ductus arteriosus in extremely low birth weight infants: Systematic review and implications for clinical practice". Ann Pediatr Cardiol 2 (2): 120–6.  
  6. ^ Alejandra Martins (2014-10-02). "The inventions of the Bolivian doctor who saved thousands of children". BBC Mundo. Retrieved 2015-03-30. 
  7. ^ 
  8. ^ MayoClinic > Patent ductus arteriosus (PDA) Dec. 22, 2009
  9. ^ Ohlsson A, Walia R, Shah SS . (2015). "Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.". Cochrane Database Syst Rev (2): CD003481.  
  10. ^ "Paracetamol (acetaminophen) for patent ductus arteriosus in preterm and low-birth-weight infants | Cochrane". Retrieved 2015-10-07. 
  11. ^ Robert E. Gross | Harvard Medical School Office for Faculty Affairs

^ Long-term Neurological Outcomes Following Neonatal Heart Surgery: Implications for Cerebral Protections in Adults. Sandra Bellezza MD. March 2, 2011

External links

  • Patent Ductus Arteriosus (PDA) - Stanford Children's Health
  • Patent Ductus Arteriosus information from Seattle Children's Hospital Heart Center
  • Patent Ductus Arteriosus Causes from US Department of Health and Human Services
  • Patent Ductus Arteriosus from Merck
  • Fetal Circulation at
  • Information about PDA - The Hospital for Sick Children
  • Down's Heart Group Easy to understand diagram and explanation of PDA.
  • PDA Occluder Amplatzer PDA occluder device used for percutaneous closure of PDAs.
  • Children's Hospital Boston Archives
  • Patent ductus arteriosus information for parents.
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.